Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Portable UTI Molecular Diagnostic Platform Provides Accurate Test Results in 40 Minutes

By LabMedica International staff writers
Posted on 09 Dec 2022

Despite being one of the most common types of infection Urinary Tract Infections (UTIs) are a comparatively neglected area of medicine. More...

There are no highly accurate diagnostic tools available for point-of-care testing. Currently, the gold standard for UTI diagnosis is to use laboratory culture but this takes at least 24 hours and often involves the transportation of the sample, adding further delay. The absence of fast diagnostic testing means clinicians make treatment decisions based on vague clinical symptoms or inaccurate urine dipstick tests. Now, a rapid and affordable point-of-care molecular diagnostics platform developed specifically to detect bacterial and viral infections aims to change that.

Llusern Scientific Limited’s (Wales, UK) Lodestar DX is a user-friendly, portable molecular platform for testing UTIs and respiratory diseases that provides lab-accurate test results in 30 minutes. The low cost platform technology allows users to conveniently carry out Loop-mediated isothermal amplification (LAMP) reactions. The technique allows amplification and detection of DNA or RNA in a wide range of bacterial and viral targets. Lodestar DX uses an internal algorithm to determine if a LAMP reaction is positive or negative. The algorithm is suitable for use with a wide range of LAMP reactions. The Lodestar DX system outputs the fluorescent reaction data in real time which can be captured directly onto a PC and stored for subsequent off-line analysis. The system can run eight reactions simultaneously and can be operated flexibly based on user needs. It can be operated from the mains supply using its powers adapter or using a 15Vdc source such as a standard vehicle lighter plug, allowing usage in remote settings.

In 2023, Llusern plans to launch a panel of Urinary Tract Infection (UTI) assays including E-coli, Klebsiella and Staphylococcus spp that run on Lodestar DX. Currently undergoing clinical validation, Llusern’s UTI test has a preliminary sensitivity of 95% for E.coli and can detect over 95% of all uropathogens. Easy to use, it does not require sample processing and urine is added directly into the assay tubes for results delivered in 30 minutes. The simple test preparation and ease of use of the Lodestar DX makes it a useful tool in doctor’s offices, clinics and pharmacies. Llusern's molecular diagnostic test for UTIs is a significant step-forward in addressing a huge everyday health problem faced by hundreds of millions of people around the globe.

Related Links:
Llusern Scientific Limited 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.